Authors’ Reply to the Letter to the Editor by Liu and Kesselheim

Authors:
Bridget Doherty Janssen Scientific Affairs, Titusville, NJ

Search for other papers by Bridget Doherty in
Current site
Google Scholar
PubMed Close
 MPH
,
Silas Martin Janssen Scientific Affairs, Titusville, NJ

Search for other papers by Silas Martin in
Current site
Google Scholar
PubMed Close
 MS
, and
Ágnes Benedict Evidera/PPD, Vienna, Austria

Search for other papers by Ágnes Benedict in
Current site
Google Scholar
PubMed Close
 MS
Volume/Issue:
Volume 22: Issue 7
Online Publication Date:
Sep 2024
DOI:
https://doi.org/10.6004/jnccn.2024.7064
Restricted access
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Liu ITT, Kesselheim AS. Letter to the Editor: Re: “Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model”. J Natl Compr Canc Netw 2024;22:e247043.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    The Food and Drug Omnibus Reform Act (FDORA) (Sec. 3210) amended Section 506(c) of the FD&C Act (21 U.S.C. 356(c)). Accessed July 10, 2024. Available at: https://www.congress.gov/bill/117th-congress/house-bill/2617/text

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern Med 2019;179:642–647.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2024 by the National Comprehensive Cancer Network 2024
Article Category:
Reply
Print Publication Date:
01 Sep 2024
Online Publication Date:
Sep 2024

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 51 51 51
PDF Downloads 36 36 36
EPUB Downloads 0 0 0